Evidence map›Paper›PMID 36359232›Full record

ArticleBiomedicines2022

Therapeutic Effects of Omentin-1 on Pulmonary Fibrosis by Attenuating Fibroblast Activation via AMP-Activated Protein Kinase Pathway.

Yan Zhou, Yunna Zhang, Haipeng Cheng, Xiaohong Li, Dandan Feng, Shaojie Yue, Jianping Xu, Hui Xie, Ziqiang Luo

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yan ZhouDepartment of Physiology, Xiangya School of Medicine, Central South University, Changsha 410013, China.ORCID 0000-0002-8822-5276
Yunna ZhangDepartment of Physiology, Xiangya School of Medicine, Central South University, Changsha 410013, China.
Haipeng ChengDepartment of Physiology, Xiangya School of Medicine, Central South University, Changsha 410013, China.
Xiaohong LiDepartment of Physiology, Xiangya School of Medicine, Central South University, Changsha 410013, China.
Dandan FengDepartment of Physiology, Xiangya School of Medicine, Central South University, Changsha 410013, China.
Shaojie YueDepartment of Pediatrics, Xiangya Hospital, Central South University, Changsha 410008, China.
Jianping XuDepartment of Physiology, Xiangya School of Medicine, Central South University, Changsha 410013, China.
Hui XieDepartment of Orthopedics, Xiangya Hospital, Central South University, Changsha 410008, China.
Ziqiang LuoDepartment of Physiology, Xiangya School of Medicine, Central South University, Changsha 410013, China.ORCID 0000-0002-3808-6159
Central South University · CN

Funding

National Natural Science Foundation of China 81870059National Natural Science Foundation of China 82070068National Natural Science Foundation of China 82200085Natural Science Foundation of Changsha kq2202116Natural Science Foundation of Hunan Province of China 2020JJ5813
6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) is a fatal age-related chronic lung disease, characterized by progressive scarring of the lungs by activated fibroblasts. The effect of omentin-1 against pulmonary fibrosis and fibroblast activation has not been investigated. The purpose of this experiment is to investigate the role of omentin-1 in bleomycin (BLM)-induced lung fibrosis and its mechanism. Our results showed that the loss of omentin-1 exaggerated lung fibrosis induced by BLM. On the contrary, adenoviral-overexpression of omentin-1 significantly alleviated BLM-induced lung fibrosis both in preventive and therapeutic regimens. Moreover, omentin-1 prevented fibroblast activation determined by a decreased number of S100A4

Indexed as

AMPK pathwaybleomycinfibroblast activationlung fibrosismyofibroblastomentin-1

Identifiers

PMID36359232
PMCPMC9687324
OpenAlexW4307555703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.